Stock Market Reviews

MDXH (MDxHealth SA) News

Get the latest news, insights, and market updates on MDXH (MDxHealth SA). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025
  Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025 Q3 revenues increased by 18% to $27.4 millionAdjusted EBITDA profitability of $1.0 million for Q3Acquisition of ExoDx business from Bio-Techne CorporationConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA – November 12, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for th
  Nov 12, 2025 - $MDXH
• Mdxhealth to Release Third Quarter 2025 Financial Results on November 12
  Mdxhealth to Release Third Quarter 2025 Financial Resultson November 12 Company to Host Conference Call with Live Q&A, November 12, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – November 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2025, after market close on Wednesday, November 12, 2025. Title:Mdxhealth Presents Third Quarter 2025 Financial Res
  Nov 3, 2025 - $MDXH
• Here's Why Momentum in MDxHealth SA (MDXH) Should Keep going
  If you are looking for stocks that are well positioned to maintain their recent uptrend, MDxHealth SA (MDXH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
  Oct 29, 2025 - $MDXH
• MDxHealth Completes Bio Techne ExoDx Acquisition to Bolster Precision Diagnostics
  MDxHealth SA (NASDAQ:MDXH) is among the best fundamentally strong penny stocks to buy right now. On September 15, 2025, MDxHealth SA (NASDAQ:MDXH) announced the completion of its acquisition of Bio-Techne Corporation’s ExoDx business, including the ExoDx Prostate test. This $15 million transaction is part of the company’s plan to strengthen its precision diagnostics portfolio. Earlier […]
  Sep 21, 2025 - $MDXH
• Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne
  Mdxhealth Announces Closing of Exosome Diagnostics Acquisition from Bio-Techne IRVINE, CA, and HERSTAL, BELGIUM – September 15, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the closing of the ExoDx business acquisition from Bio-Techne Corporation, which includes the ExoDx Prostate test. Acquisition of ExoDx Business On August 5, 2025, mdxhealth signed a definitive agreement to acquire Exosome Diagnosti
  Sep 15, 2025 - $MDXH
• MDxHealth SA (MDXH) Reports Q2 Loss, Tops Revenue Estimates
  MDxHealth SA (MDXH) delivered earnings and revenue surprises of -15.38% and +0.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
  Aug 6, 2025 - $MDXH
• MDxHealth SA (MDXH) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ...
  MDxHealth SA (MDXH) achieves its first quarter of adjusted EBITDA profitability and announces a transformative acquisition, despite ongoing financial challenges.
  Aug 6, 2025 - $MDXH
• Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne
  Mdxhealth Reports Preliminary Second Quarter 2025 Results, Reaches Positive Adjusted EBITDA, and Announces Acquisition of Exosome Diagnostics Business from Bio-Techne Year-over-year Q2 revenues increased by 20% to $26.6 millionAdjusted EBITDA profitability of $1.4 million for Q2 Agreement to acquire ExoDx Business from Bio-Techne for $15 million in cash and stock over 5 years; acquisition expected to accelerate revenue growth and be accretive to adjusted EBITDA Conference call with Q&A today at
  Aug 5, 2025 - $MDXH
• Bio-Techne Announces Exosome Diagnostics Divestiture
  Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar.
  Aug 5, 2025 - $MDXH
• Mdxhealth Appoints Michael Holder to Board of Directors and Announces Management Change
  IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles
  Jul 3, 2025 - $MDXH